Literature DB >> 11886599

The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis.

G Steinhoff1, B Ittah, S Rowan.   

Abstract

OBJECTIVE: An open label study of chondroitin sulfate was undertaken to determine the response of patients with interstitial cystitis and positive potassium test results to this agent.
METHOD: Eighteen patients with classic features of interstitial cystitis were enrolled in the study. Patients received 40 mL chondroitin sulfate, 0.2% instilled intravesically once a week for four weeks and then once a month for 12 months. At the same times, Quality of Life Improvement scores, voiding diaries, and pain and voiding indices were reviewed.
RESULTS: Thirteen of 18 patients were followed for the entire 13-month study. Twelve of these patients responded to treatment within 3 to 12 weeks, on average. A total of 6/13 (46.2%) showed a good response, 2/13 (15.4%) had a fair response, and 4/13 (30.8%) had a partial response and 1/13 (7.7%) showed no response.
CONCLUSION: Intravesical chondroitin sulfate seems to demonstrate some beneficial effects in treatment of interstitial cystitis patients who have positive potassium stimulation test results.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11886599

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  15 in total

Review 1.  A Practical Approach to the Management of Radiation-Induced Hemorrhagic Cystitis.

Authors:  Xavier Liem; Fred Saad; Guila Delouya
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

2.  Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis.

Authors:  Omer Gülpınar; Aytaç Kayış; Evren Süer; Mehmet İlker Gökçe; Adil Güçal Güçlü; Nihat Arıkan
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

3.  Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis.

Authors:  Paul F Engelhardt; Nike Morakis; Lukas K Daha; Britta Esterbauer; Claus R Riedl
Journal:  Int Urogynecol J       Date:  2010-10-12       Impact factor: 2.894

4.  Outcomes of intravesical chondroitin-sulfate and combined hyaluronic-acid/chondroitin-sulfate therapy on female sexual function in bladder pain syndrome.

Authors:  Burak Arslan; Serkan Gönültaş; Ersin Gökmen; Oktay Özman; Mustafa Asım Avci; Enver Özdemir
Journal:  Int Urogynecol J       Date:  2019-06-28       Impact factor: 2.894

Review 5.  Treatment approaches for painful bladder syndrome/interstitial cystitis.

Authors:  Theoharis C Theoharides
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate.

Authors:  Paul J Hauser; David A Buethe; John Califano; Troy M Sofinowski; Daniel J Culkin; Robert E Hurst
Journal:  J Urol       Date:  2009-09-17       Impact factor: 7.450

7.  Hyaluronan treatment of interstitial cystitis/painful bladder syndrome.

Authors:  Claus R Riedl; Paul F Engelhardt; Kurosch L Daha; Nike Morakis; Heinz Pflüger
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-12-21

Review 8.  Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence.

Authors:  Massimo Lazzeri; Rodolfo Hurle; Paolo Casale; NicolòMaria Buffi; Giovanni Lughezzani; Girolamo Fiorini; Roberto Peschechera; Luisa Pasini; Silvia Zandegiacomo; Alessio Benetti; Gianluigi Taverna; Giorgio Guazzoni; Guido Barbagli
Journal:  Ther Adv Urol       Date:  2015-12-16

9.  The effects of intravesical pentosanpolysulfate treatment on the symptoms of patients with bladder pain syndrome/interstitial cystitis: preliminary results.

Authors:  Lukas K Daha; Dara Lazar; Reiner Simak; Heinz Pflüger
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-29

Review 10.  Intravesical treatments of bladder pain syndrome/interstitial cystitis.

Authors:  Jochen Neuhaus; Thilo Schwalenberg
Journal:  Nat Rev Urol       Date:  2012-11-27       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.